Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
- Conditions
- Cognitive DeclineGlioblastomaRadiotherapy; ComplicationsChemoradiation
- Interventions
- Registration Number
- NCT03475186
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
- Detailed Description
This is a pilot study of an oral drug Ramipril to prevent cognitive decline in glioblastoma patients receiving partial brain radiation and concurrent and adjuvant temozolomide . Ramipril will be titrated to the highest tolerable dose during chemoradiation (2.5-5 mg). Once this dose is determined, the patient will continue at this dose for 4 months after the completion of chemoradiation. Patients will be followed until 5 months post chemoradiation for compliance, toxicity, cognitive decline and participant reported outcomes (PRO).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 75
- Histologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) obtained at the time of a partial or gross total resection of the tumor. Patients who undergo a stereotactic needle biopsy alone are not eligible.
- The tumor must have a supratentorial component.
- History/physical examination within 14 days prior to enrollment.
- The patient must have recovered from the effects of surgery, postoperative infection, and other complications before enrollment
- Patient planning to receive brain RT, and concurrent and adjuvant temozolomide chemotherapy for six weeks as per standard of care therapy. Use of the Optune® (also known as Tumor Treating Fields or TTFields) device is allowed at provider discretion, but must begin after the Month 1 Post RT (10 week [wk]) Neurocognitive-PRO assessment.
- Study drug (Ramipril) must be given >= 21 days and ≤ 42 days after surgery.
- All available brain magnetic resonance imaging (MRI) or computed tomography (CT) imaging reports from surgery to study completion must be submitted. This includes any post-operative or pre-radiation scan reports.
- Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2
- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (obtained within 14 days prior to enrollment)
- Platelets >= 100,000 cells/mm^3 (obtained within 14 days prior to enrollment)
- Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (obtained within 14 days prior to enrollment)
- Blood urea nitrogen (BUN) =< 30 mg/dl within 14 days prior to enrollment
- Creatinine =< 1.7 mg/dl within 14 days prior to enrollment
- Total bilirubin =< 2.0 mg/dl within 14 days prior to enrollment
- Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x normal range within 14 days prior to enrollment
- Patient must provide study specific informed consent prior to study entry
- Baseline potassium level <5.0 mEq/L. High potassium values that are thought to be a result of sample hemolysis may be repeated to determine an accurate potassium level and to determine potential study eligibility. Likewise high potassium values thought to be a result of potassium supplementation may be repeated at an appropriate time (5 half-lives after supplement discontinuation) to determine potential study eligibility.
Patient must be able to complete neurocognitive tests in the English language
- Women of childbearing potential and male participants must practice adequate contraception
- For females of child-bearing potential, negative serum or urine pregnancy test within 14 days of enrollment
- Local site must be follow the standard GBM radiation treatment dosimetry plan
- For patients who will be treated with the Optune® device in addition to standard of care radiation plus concurrent and adjuvant temozolomide, the following inclusion criteria also apply:
- Patients must have only a supratentorial glioblastoma
- The treating physician must be a qualified provider having successfully completed the training course provided by Novocure, the device manufacturer
- Patients with prior malignancies if all treatment for that malignancy was completed at least 2 years before registration and the patient has no evidence of disease.
- Prior allergic reaction or intolerance to angiotensin-converting-enzyme (ACE) inhibitor
- Hypotension (< 110 mg Hg systolic) at the time of enrollment
- Renal insufficiency with creatinine clearance of < 40 ml/min (at time of enrollment)
- Solitary kidney or known renal artery stenosis
- Current ACE inhibitor or angiotensin receptor blocker use. Patients can come off ACE inhibitors or angiotensin receptor blockers for 1 week to be eligible for this study.
- Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 2 years. (For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible).
- Recurrent or multifocal malignant gliomas
- Metastases detected below the tentorium or beyond the cranial vault
- Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable, except prior temozolomide. Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted.
- Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields.
- Severe active co-morbidity, defined as follows:
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of enrollment.
- Known HIV positivity or acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
- Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
- Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study unless they involve standard of care or over the counter therapies or do not involve a drug therapy.
- Patients planning to receive therapeutic antitumor agents (excluding use of the Tumor Treating Fields (TTFields or Optune®) device after the Month 1 Post RT (10 wk) Neurocognitive-PRO assessment.) in addition to standard radiation and concurrent and adjuvant temozolomide are not eligible to participate in this study.
- Patients with impaired decision-making capacity; this exclusion is necessary because such patients may not be able to adequately give informed consent.
- Pregnant or lactating women, due to possible adverse effect on the developing fetus or infant due to study drug.
- For patients who will be treated with the Optune® device in addition to standard of care radiation plus concurrent and adjuvant temozolomide, the following exclusion criteria also apply:
- Optune® is not permitted in patients who have an active implanted medical device, skull defect (such as, missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmatic shunts.
- Optune® is not permitted in patients who are known to be sensitive to conductive hydrogels. Examples of conductive hydrogels are gels used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.
- Patients being treated with Memantine, Donepezil, and/or medications prescribed to enhance cognition.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ramipril Ramipril Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
- Primary Outcome Measures
Name Time Method Change from Baseline Neurocognitive Function at 10 weeks - Hopkins Verbal Learning Test-Revised (HVLT-R) Baseline,10 weeks HVLT-R measures verbal learning and memory. It consists of a 12-item word list which is read to subjects on three successive learning trials. Free recall scores are recorded for each learning trial. Scores for immediate recall (total of three trials), delayed recall (total number of words recalled after 20 minutes), and recognition (total number of words correctly identified) will be the variables derived from the HVLT-R.
Change from Baseline Neurocognitive Function at 10 weeks - Trail Making Test Part A and B (TMT A & B) Baseline,10 weeks Part A of the TMT measures attention and visual motor skills and processing speed and requires subjects to connect 25 numbered circles in the proper sequence (1-2-3-...) as quickly as possible. TMT-B is similar except subjects are required to connect dots in an alternating numerical and alphabetical sequence (1-A-2-B-...). TMT-B with its added complexity and set shifting requirements is a widely used measure of executive function. The score for TMT-A and TMT-B is the total time in seconds required to complete the task. Scores can also be generated for number of errors and number of circles correctly connected.
Change from Baseline Neurocognitive Function at 10 weeks - Controlled Oral Word Association Test (COWA) Baseline,10 weeks The COWA measures speed of mental processing, verbal fluency, and executive function. Subjects are asked to name as many words as possible all beginning with a specified letter. A total of three trials are administered, each with a different letter (F-A-S). The score on the COWA is the total number of words named across the three trials minus repetitions.
Efficacy of Ramipril of Neurocognitive Function at Baseline - Shipley Institute of Living Scale-Version 2 Vocabulary Baseline Provides an assessment of premorbid intellectual functioning comparable to a verbal IQ and thus is a proxy for cognitive reserve. This vocabulary test requires respondents to read a target word and select one of four words that most closely means the same thing. Score is total correct of 40 items and will be used in conjunction with the other neurocognitive results.
Retention Rate at 10 weeks 10 weeks Measured by the percent of patients who took 75% of the Ramipril doses and completed the neurocognitive battery of tests
- Secondary Outcome Measures
Name Time Method Efficacy of Ramipril on Non-Memory Cognitive Functions-EORTC Quality of Life Questionnaire-Core 30/Brain Cancer Module-20 (EORTCQLQ30/BN20) Baseline, 6 weeks, 10 weeks, 22 weeks A 50-item questionnaire with a 20-item brain cancer specific section, used to assess the physical and psychosocial functioning and symptom experience. All of the scales and single-item measures range in score from 0 to 100 with standardization.
Estimate Time of Neurocognitive Decline- HVLT-R Baseline - 22 weeks Measured by the first significant decline of the HVLT-R.
Estimate Time of Neurocognitive Decline- TMT A & B Baseline - 22 weeks Measured by the first significant decline of the TMT A \& B
Estimate Time of Neurocognitive Decline- COWA Baseline - 22 weeks Measured by the first significant decline of the COWA
Determine Presence of Apolipoprotein Epsilon (ApoE) Baseline Measured by quantitative polymerase chain reaction (PCR) using patient serum via a blood test
Efficacy of neurocognitive function in surviving patients- HVLT-R 22 weeks Comparison of HVLT-R results between groups at study end.
Efficacy of neurocognitive function in surviving patients- COWA 22 weeks Comparison of COWA results between groups at study end.
Efficacy of neurocognitive function in surviving patients- EORTCQLQ30/BN20 22 weeks Comparison of EORTCQLQ30/BN20 results between groups at study end.
Efficacy of neurocognitive function in surviving patients- TMT A & B 22 weeks Comparison of TMT A \& B results between groups at study end.
Trial Locations
- Locations (420)
Anchorage Associates in Radiation Medicine
🇺🇸Anchorage, Alaska, United States
Anchorage Radiation Therapy Center
🇺🇸Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC
🇺🇸Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC
🇺🇸Anchorage, Alaska, United States
Alaska Women's Cancer Care
🇺🇸Anchorage, Alaska, United States
Anchorage Oncology Centre
🇺🇸Anchorage, Alaska, United States
Katmai Oncology Group
🇺🇸Anchorage, Alaska, United States
Providence Alaska Medical Center
🇺🇸Anchorage, Alaska, United States
Cancer Center at Saint Joseph's
🇺🇸Phoenix, Arizona, United States
Mercy Hospital Fort Smith
🇺🇸Fort Smith, Arkansas, United States
Scroll for more (410 remaining)Anchorage Associates in Radiation Medicine🇺🇸Anchorage, Alaska, United States